Dermatology | Home | MIMS Malaysia

Secukinumab triumphs over ustekinumab for moderate-to-severe plaque psoriasis

Roshini Claire Anthony, 3 days ago

The fully human monoclonal antibody secukinumab triumphed over ustekinumab once again in patients with moderate-to-severe plaque psoriasis, according to the phase IIIb CLARITY* trial presented at the recent annual meeting of the American Academy of Dermatology (AAD 2019).

Risankizumab outdoes ustekinumab in plaque psoriasis

Audrey Abella, 3 days ago

The humanized immunoglobulin G1 monoclonal antibody risankizumab provided durable clinical efficacy compared with ustekinumab in individuals with moderate-to-severe plaque psoriasis, according to integrated analyses of UltIMMa-1 and 2* presented at AAD 2019.

Tildrakizumab yields durable responses for psoriasis

Audrey Abella, 4 days ago

Long-term use of the humanized immunoglobulin G1K monoclonal antibody tildrakizumab generated durable responses in adult patients with moderate-to-severe chronic plaque psoriasis*, according to the results of the 3-year extension phases of reSURFACE 1** and 2*** presented at AAD 2019.

Omadacycline a potential treatment for bacterial skin infections

Roshini Claire Anthony, 15 Mar 2019

The aminomethylcycline antibiotic omadacycline is as efficacious as linezolid in treating bacterial skin and skin structure infections, according to the phase III OASIS-1* trial.

Topical mTOR inhibitors safe, effective in angiofibromas

12 Mar 2019

Topical use of mammalian target of rapamycin (mTOR) inhibitors is effective for angiofibromas linked to tuberous sclerosis complex, with mild to moderate side effects only, according to the results of a recent systematic review.

Bridging the Gap in Atopic Dermatitis Management

22 Jan 2019

In conjunction with the launch of QV Intensive with Ceramides (Ego Pharm), the important role of ceramides in themanagement of atopic dermatitis (AD) was highlighted by two distinguished speakers, Dr Agnes Heng of KPJ and Pantai Hospital Ipoh, as well as Dr Fabrizio Spada of Ego Pharmaceuticals, Australia.

Antihistamine therapy for allergic rhinitis and urticaria: An Asia-Pacific perspective

01 Nov 2018

The prevalence of allergic diseases in the Asia-Pacific region is expected to rise over the next 20 years, driven by rapid economic development and urbanization. Allergic diseases have high socioeconomic impact by impairing productivity and quality of life, and the impact may be greater in Asia-Pacific than in Europe due to the presence and predominance of perennial allergens.

Improved wound healing rates with micronutrients consumption

31 Jul 2018

A wound is a disruption of the normal structure and function of the epidermis. Wounds maybe caused by acute traumatic injury to the skin, or other aetiologies that cause initially intact skin to break down. Recently, Dato’ Dr Ho Teik Kok shared his insights into the importance of micronutrients for wound recovery, stressing on the importance of treating the underlying diseases that may impede wound healing.

Improving Medical Practice through Advancement in Clinical Treatment: IMPACT Aesthetics & Suturing Workshop 2018

Dr. Steven Ang, Dr. Leo Kah Woon, 11 Jul 2018

DCH Auriga recently held their first Aesthetics and Suturing Workshop under the IMPACT continuing medical education series – a scientific platform that aims to cascade the latest updates on disease management and share best clinical practices among healthcare professionals in Singapore. Two experts on aesthetics and aesthetic surgery shared their insights on suturing techniques and current approaches for scar prevention and management.

Cochrane review confirms Atopiclair efficacy in eczema

22 Dec 2017

Eczema (atopic dermatitis) is a chronic inflammatory skin disease that can present in many different forms. However, it is principally characterized by dry skin, intense itching, and the presence of inflammatory skin lesions. [J Eur Acad Dermatol Venereol 2016;30:604-618; N Engl J Med 2008;358:1483-1494; Lancet 2016;387:1109-1122]

Management of atopic dermatitis with topical calcineurin inhibitor

04 Dec 2017

At the 42nd Annual Dermatology Conference 2017 held recently in Kuala Lumpur, Professor Michael J. Cork spoke on the interaction between genetic and environmental factors as a primary event in the development of atopic dermatitis (AD) and highlighted the role of topical calcineurin inhibitors (TCIs) in the management of AD.

Beyond skin-deep: The role of topical calcineurin inhibitors in the treatment of atopic dermatitis

17 Aug 2017

The prevalence of atopic dermatitis (AD) in industrialized countries has increased exponentially over the past three decades, currently affecting 15 to 30% of children and up to 10% of adults.¹ At the recent official launch event of pimecrolimus (Elidel^®, Meda Healthcare Sdn. Bhd.) held at Le Méridien Kuala Lumpur, Professor Thomas Luger provided insights on the pathophysiology of AD and the role of topical calcineurin inhibitors (TCIs) in the management of AD.

Secukinumab triumphs over ustekinumab for moderate-to-severe plaque psoriasis

Roshini Claire Anthony, 20 Mar 2019

Risankizumab outdoes ustekinumab in plaque psoriasis

Audrey Abella, 20 Mar 2019

Tildrakizumab yields durable responses for psoriasis

Audrey Abella, 19 Mar 2019

Secukinumab demonstrates long-term benefit in active psoriatic arthritis

Roshini Claire Anthony, 21 Jan 2019

The benefits of the fully human monoclonal antibody secukinumab at doses of either 150 or 300 mg weekly in patients with active psoriatic arthritis are sustained even after 4 years, according to updated results of the FUTURE 2* study presented at the Inflammatory Skin Disease Summit (ISDS 2018).

Risankizumab improves skin appearance in patients with plaque psoriasis

Elaine Soliven, 19 Jan 2019

Treatment with risankizumab, an interleukin-23 inhibitor, significantly improves skin appearance in patients with moderate-to-severe plaque psoriasis, according to the IMMvent* study presented at the Inflammatory Skin Disease Summit (ISDS).

Guselkumab tops secukinumab for moderate-to-severe plaque psoriasis

Roshini Claire Anthony, 17 Jan 2019

Individuals with moderate-to-severe plaque psoriasis may reap better long-term improvements in the severity of their condition when treated with guselkumab over secukinumab, according to findings of the phase III ECLIPSE* trial presented at the recent Inflammatory Skin Disease Summit (ISDS 2018) held in Vienna, Austria.